Medipharm Labs Corp T.LABS

Why grumble .... LABS is improving ....

[prone]

--->Adjusted EBITDA(1): Negative $743K in the three months ended September 30, 2024 ("Q3 2024"), significantly improved from negative $2.4M during the same period in 2023 ("Q3 2023").

Net Revenue: $9.8M in Q3 2024, a 15% increase as compared to Q3 2023.

International medical cannabis revenue grew 37% versus Q3 2023 and represented 36% of revenues in the quarter.

Canadian medical and business to business sales represented 46% of total revenue in Q3 2024.

[QContinuum1]

I grumble because they're not. 

[alleyesonme]

9 months ending sept 30th, revenue is up 25% as compared to the same period last year, German flower sales, measly, however up to 400k from 124k, it appears dronabinol dropped off a cliff this Q...order timing or did or client move suppliers, explanation warranted. 

[QContinuum1]

Topline off from Q2, drob off a cliff, Australia flat, Canada cratered, Germany grew (if you can call it that) in a market that is apparently to be 400 million euros (med only) in 2024 with a massive partner.  One could argue that Germany didn't grow given the market explosion, akin to getting a 2% raise when inflation is actually 3%, your salary increased, but did it really? So no, LABS

[Starkicker]

All of that is true QC. If they are one of the few, if not the only ones, able to navigate highly regulated markets as they claim, then why such pitiful revenue? Somebody needs to explain that. Also, it was a year ago Pidduck assured us the adjusted ebitda would be in the positive and has yet to deliver. Red flags everywhere.

[CADInvestor12]

I don't disagree that Q3 was disappointing but you are completely wrong with your analysis of the financials ..  Australia is up 11% QoQ - All of Canada up 6.5% QoQ .. Germany is where it all went wrong, if revenue held flat from Q2, then we would've been looking at overall QoQ growth of 7%. Seems like they are never able to completely put the package together - Q2 Australia &

[QContinuum1]

Australia was flat YoY and Canada was essentially the same.  Personally I don't see $200k increases on $2.5m as material increases, when all the guidance we have ever been given is just wait until these new reg requirements make their way through the system.  You can't decide to report Topline increases YoY and then decide to dig into the numbers to look for QoQ increases. 

[CADInvestor12]

LOL .. it amazes me how you can be sensible in one post and an utter moron in another, case and point... Not sure who makes me laugh more, you or Lemoyne.. Australia: 9-month Rev 2023 - $4.276M / 9-month Rev 2024 - $6.447M Germany: 9-month Rev 2023 - $2.582M/ 9-month Rev 2024 - $4.738M  Canada (combined): 9-month Rev 2023 - $16.381M/ 9-month Rev 2024 - $18.599M/

[QContinuum1]

Well how's that for a hi how are ya? So you're looking at nine months ending, I see.  I was looking at same Q. And I am plenty smart enough to understand that some things are out their control.  What part of the tighten regs in Australia or open market in Germany hurts their chances of selling into their by the boatload? No need to get nasty.  People that do tend to be

[Macpoor]

The reason , I sleep like a baby at night is that LABS has no meaningful debts. A company without Zero debts survive . I feel that good days ahead , only we need to stay focused. I have invested close to $60000 . My average is 16 cents, I wait few more years. It is what it is. Cheers